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This work aimed to establish the role of gne (encoding UDP-GalNAc 4-epimerase activity) and galE (encod-
ing UDP-Gal-4-epimerase activity) in the biosynthesis of surface polysaccharides, as well as in the virulence for
eels and humans of the zoonotic serovar of Vibrio vulnificus biotype 2, serovar E. DNA sequence data revealed
that gne and galE are quite homologous within this species (>90% homology). Mutation in gne of strain
CECT4999 increased the surface hydrophobicity, produced deep alterations in the outer membrane architec-
ture, and resulted in noticeable increases in the sensitivity to microcidal peptides (MP), to eel and human sera,
and to phagocytosis/opsonophagocytosis. Furthermore, significant attenuation of virulence for eels and mice
was observed. By contrast, mutation in galE did not alter the cellular surface, did not increase the sensitivity
to MP, serum, or phagocytosis, and did not affect the virulence for fish and mice. The change in the
attenuated-virulence phenotype produced by a mutation in gne was correlated with the loss of the O-antigen
lipopolysaccharide (LPS), while the capsule was maintained. Complementation of a gne-deficient mutant
restored the LPS structure together with the whole virulence phenotype. In conclusion, gne, but not galE, is
essential for LPS biosynthesis and virulence in the zoonotic serovar of V. vulnificus biotype 2.
Vibrio vulnificus is a pathogenic bacterial species that occurs
in warm aquatic environments with intermediate levels of sa-
linity. It is commonly isolated in temperate, subtropical, and
tropical areas, where it is a risk to public health. V. vulnificus is
able to infect fish and humans and causes a disease called
vibriosis (41). Human vibriosis occurs after infection of preex-
isting wounds with seawater, after an individual is injured while
fishing or handling fish, or after ingestion of raw seafood (41).
Fish vibriosis is produced after gill or intestine colonization,
without previous injury (19, 37). Human and fish vibriosis can
lead to septicemia and death if innate defenses do not act
properly and in time, which makes the mechanisms of resis-
tance of V. vulnificus to innate defenses a key virulence factor
in septicemia. Classically, the human virulent strains are clas-
sified in biotypes 1 and 3, while the fish virulent strains are
classified in biotype 2 (11, 53). Interestingly, some biotype 2
strains, which are serologically homogeneous, are able to infect
both humans and fish (3). These strains are designated serovar
E strains (VSE strains) and are distributed worldwide. Re-
cently, the genomes of two strains of V. vulnificus biotype 1
isolated from human blood in Asia have been described and
compared (15, 29). Both of these strains are serologically dif-
ferent from VSE strains (unpublished results).
A number of virulence factors that confer resistance to hu-
man innate immunity have been described for biotype 1
strains. Two such factors are the capsule that protects bacteria
from phagocytosis (58) and an iron acquisition system that
depends on vulnibactin, which is used for sequestering iron
from host transferrin (28). In VSE strains, the capsule seems
not to be essential for resistance to eel serum since spontane-
ous translucent variants survive in fresh eel serum (10), while
the lipopolysaccharide (LPS) could contribute to this resis-
tance since spontaneous O-antigen mutants that develop rug-
ose colonies are sensitive to eel serum and are avirulent (2).
No information concerning either the chemical structure of
cell surface polysaccharides or the genes involved in their bio-
synthesis in V. vulnificus VSE strain cells is available, although
several genes, such as wbpO, wbpP, and wza, have recently
been described in V. vulnificus biotype 1 (46, 47, 59). wbpO
encodes a putative UDP-N-acetyl-D-galactosamine dehydroge-
nase essential for LPS biosynthesis, wbpP encodes a putative
UDP-N-acetylglucosamine 4-epimerase essential for capsule
biosynthesis, and wza encodes a sugar transferase also needed
for capsule biosynthesis. In other bacterial species, additional
genes, such as gne (encoding UDP-N-acetylgalactosamine
[UDP-GalNAc] 4-epimerase activity) and galE (encoding
UDP-galactose [UDP-Gal] 4-epimerase activity), have been
described as genes that are involved in LPS or capsule biosyn-
thesis and virulence (12, 16).
The objective of the present work was to establish the roles
played by gne and galE in the biosynthesis of surface polysac-
charides, as well as in the virulence for fish and humans, in the
zoonotic serovar of V. vulnificus biotype 2. To this end, we
looked for both of these genes in the previously published
genome of biotype 1 strain YJ016, performed PCR to deter-
mine whether they were present in representative VSE strains,
and obtained two mutants from a selected VSE strain by allelic
exchange. The selected strain was CECT4999, originally iso-
lated from a diseased eel, which is highly virulent for both eels
and mice (an animal model used to test human virulence) and
is resistant to both eel and human sera. We demonstrated that
mutations in gne alter the O antigen of the LPS but not the
capsule. The gne-deficient mutant showed significant attenua-
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tion of virulence for mice and eels, but the galE-deficient
mutant did not show significant attenuation.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. Bacterial strains and plas-
mids used in this work are shown in Table 1. V. vulnificus strains were grown in
tryptic soy broth containing 1% NaCl (TSB-1), on tryptic soy agar containing 1%
NaCl (TSA-1), in marine seawater yeast extract (MSWYE), on MSWYE agar
(42), and in M9 minimal medium (50) supplemented with 10 mM MgSO4, 10
mM CaCl2, and 20% Casamino Acids (Difco) at 28°C for 24 h. For enzymatic
determinations, the strains were cultured in Davis minimal medium (13) with
0.2% glucose (DMM-glu) or galactose (DMM-gal) as the only carbon source.
Escherichia coli and Salmonella enterica serotype Typhimurium strains were
grown in Luria-Bertani broth and on Luria-Bertani agar at 37°C for 24 h. When
required, ampicillin (Amp) (100 g ml1), rifampin (Rif) (100 g ml1), or
chloramphenicol (Cm) (20 g ml1) was added to the different media. All the
strains were stored in TSB-1 with or without an antibiotic plus dimethyl sulfoxide
at 80°C. All bacterial counts were obtained by using the drop plate method-
ology (26).
General DNA methods, DNA sequencing, and computer analysis of sequence
data. General DNA manipulations were performed as previously described (50).
DNA restriction endonucleases, T4 DNA ligase, E. coli DNA polymerase
(Klenow fragment), and alkaline phosphatase were used as recommended by the
suppliers. Double-stranded DNA sequencing was performed by using the
dideoxy chain termination method (50) with an ABI Prism dye terminator cycle
sequencing kit (Perkin-Elmer). Oligonucleotides were purchased from Pharma-
cia LKB Biotechnology. The DNA sequence was translated in open reading
frames with the Frameplot program (27) and was compared with DNA se-
quences from the nonredundant GenBank (National Center for Biotechnology
Information) and EMBL (European Biotechnology Information Service) data-
bases by using the BLAST network service (1). ClustalW was used for multiple-
sequence alignment.
DNA amplification and plasmid and mutant construction. The VV3026 and
VV2639 genes of biotype 1 strain YJ016 (accession number BA000037) were
selected for primer design to detect putative gne and galE genes in VSE cells due
to their homology to gne and galE of Aeromonas hydrophila AH-3 (12) (Fig. 1).
The primers used for gne amplification were gne for (5-TTTCAGTTCGTCAG
CCACC-3) and gne rev (5-TCAGCAATATCACCGGCAC-3), which resulted
in a 531-bp amplicon; and the primers used for galE amplification were galE for
(5-TGACATTCGTGACGAAGCC-3) and galE rev (5-TCCCCACCGATTT
CAATGC-3), which resulted in a 584-bp amplicon. These amplicons were
subcloned as incomplete copies (with an internal sequence missing both the 5
and 3 ends) of the gne and galE genes in the vector pGEMT, creating pGEMT-
gne and pGEMT-galE. After EcoRI digestion of plasmids pGEMT-gne and
pGEMT-galE, the gel-purified DNA was treated with E. coli DNA polymerase I
(Klenow fragment) to create blunt ends in order to ligate the band to pCM100
(suicide plasmid, pir dependent) and obtain plasmids pCM100-gne and
pCM100-galE. Plasmids pCM100-gne and pCM100-galE were used to obtain gne-
and galE-deficient mutants from CECT4999 by a single recombination event
using previously described procedures (50). To this end, pCM100-gne and
pCM100-galE were isolated, transformed into E. coli MC1061-pir (12), and
transferred by triparental conjugation to strain CECT4999-0 (a spontaneous
rifampin-resistant [Rifr] mutant) as previously described (12). The Cmr Rifr
transconjugants should have contained the mobilized plasmid integrated into the
chromosome by homologous recombination, leading to two incomplete copies of
the gne and/or galE gene (defined insertion mutants). Complementation analysis
of the different VSE mutants was performed by conjugal transfer of wild-type
complete galE and gne genes cloned in pGEMT to the corresponding mutants.
Recombinants were selected on TSA-1 containing Cm, Rif, and Amp. Additional
transformation experiments with pGEMT-gne and pGEMT-galE were per-
formed with strains DH5 (which naturally lacks UDP-GalNAc 4-epimerase
activity) (23) and SL1306 (a mutant that lacks UDP-Gal 4-epimerase activity)
(54).
Cell extract production and measurement of enzymatic activity (UDP-Gal
4-epimerase and UDP-GalNAc 4-epimerase assays). Suspensions of bacteria
(25%, wt/vol) that were washed in 25 mM Tris-HCl buffer (pH 7.5) containing 1
mM MgCl2 were disrupted with a Branson model 350 Sonifier at 0°C. The
disrupted bacteria were subjected to high-speed centrifugation (180,000  g for
2 h) at 5°C to obtain cell extracts. Protein concentrations of extracts were
determined by using the Bio-Rad Bradford assay as recommended by the man-
ufacturer with bovine serum albumin as the standard.
The assays for UDP-Gal 4-epimerase and UDP-GalNAc 4-epimerase activities
were performed as previously described (17, 57). For UDP-Gal 4-epimerase, the
initial rates of NADH formation were determined by using the kinetics program
installed in the spectrophotometer (Beckman DU640). A molar extinction co-
efficient (340) of 6.220 M1 cm1 was assumed for all calculations. For UDP-
GalNAc 4-epimerase, the conversion of UDP-GalNAc to UDP-N-acetylglu-
cosamine (GlcNAc) was measured after acid hydrolysis by the 3.6-fold-greater
absorbance at 585 nm (A585) of free GlcNAc than of GalNAc in the Morgan-
Elson reaction. Following hydrolysis and completion of the Morgan-Elson reac-
tion, color development was measured at 585 nm. Control assays with extract and
with only substrate were performed simultaneously. All assays were performed in
triplicate. Product formation (i.e., formation of GlcNAc by hydrolysis of UDP-
GlcNAc) was measured using standard plots prepared by subjecting UDP-
GlcNAc, UDP-GalNAc, GlcNAc, and GalNAc (Sigma-Aldrich, St. Louis, MO)
to the same procedures.
Electron microscopy. To stain flagella, cell suspensions were mixed with 2%
phosphotungstic acid (pH 7) and air dried. Ultrastructural studies of the bacte-
rial envelopes were performed by using ruthenium red staining for polysaccha-
rides as described by Biosca et al. (10). Briefly, agar pieces with bacteria were
placed into sodium cacodylate buffer (0.2 M, pH 7.2) containing 2.5% glutaral-
dehyde plus 0.075% ruthenium red, washed with sodium cacodylate buffer, and
incubated for 2 h at 4°C in 1% osmium tetroxide. Then samples were washed in
ultrapure MilliQ water, dehydrated using a graded ethanol series (30 to 100%
ethanol, 10 min per step), and transferred sequentially into 3:1, 1:1, and 1:3
ethanol-epoxy resin (Aname) for 1 h per step and finally into 100% resin over-
night. Then samples were embedded in flat silicone molds and placed inside a
60°C oven to polymerize for 2 days. Blocks were removed from the molds, and
100-nm ultrathin sections were obtained using a Leica Ultracut R ultrami-
crotome (Leica Microsystems, Milton Keynes, England). Observations were
made with a JEOL 1010 transmission electron microscope.
MICs of microcidal peptides (MP) and human transferrin. Stationary-phase
bacteria were suspended in phosphate-buffered saline (pH 7) containing 1%
NaCl (PBS-1) at a concentration of approximately 107 CFU ml1, and 10 l was
inoculated into MSWYE plates containing polymyxin B sulfate (500 to 105 U
ml1; Sigma), poly-L-lysine (30 to 300 g ml; Sigma), or transferrin (2.5 to 50
M; Sigma) and incubated for 24 h at 28°C. The MIC endpoint was defined as
the lowest antibiotic concentration at which there were no visible colonies.
Experiments were carried out in triplicate.
Antigen extraction, separation, and visualization. Outer membrane proteins
(OMP) were obtained from cells after sonication and differential solubilization
of the inner membranes in a Sarkosyl solution (0.05%) as described by Biosca et
al. (9). The extracellular proteins (ECP) were obtained after separation by
differential centrifugation from cells grown on cellophane sheets covering TSA-1
plates using the protocol of Liu (34). OMP and ECP concentrations of samples
were determined by the method of Lowry et al. (35). Crude fractions of bacterial
polysaccharides (LPS and capsule) were obtained from cell lysates after protein-
ase K digestion (Boehringer Mannheim) as described by Hitchcock and Brown
(25). The LPS concentration was determined with ProQ Emerald 300 staining for
glycoproteins (Invitrogen) by following the manufacturer’s instructions. OMP,
ECP, LPS, and capsule antigens were separated and examined by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (30) in discontinuous gels (4%
stacking gel, 12% separating gel). Protein bands were visualized by Coomassie
brilliant blue staining, and LPS and capsule bands were visualized by immuno-
staining after transfer from the polyacrylamide gels to nitrocellulose sheets (0.45
m; Bio-Rad) as described by Towbin et al. (55). Blotting was done at 200 mA
for 2 h in Tris-glycine-methanol transfer buffer (25 mM Tris, 192 mM glycine [pH
8.3], 20% [vol/vol] methanol). Immunostaining was performed with previously
obtained serovar-specific sera (4) (dilution for immunostaining, 1:1,000) or with
the same sera after absorption with one of the mutants. The absorption process
involved incubating serum with mutant cells (1  109 CFU per ml in PBS-1) with
gentle shaking for 30 min at 37°C, followed by filtration through 0.22-m-pore
size membranes (Millipore filters) (43). Absorbed sera were diluted 1:10 for
immunostaining (43).
Eel serum, mucus, and phagocyte collection. Humoral (serum and gill mucus)
and cellular (head kidney, spleen, and blood phagocytes) defensive factors were
obtained from adult eels (Anguilla anguilla) as described by Esteve-Gassent et al.
(18) and Castro et al. (14), respectively. For the cellular factors, the head kidney
and spleen were aseptically removed and crushed, and blood was taken from the
caudal vein; these factors were mixed (1:3) with Leibovitz’s medium (L-15)
(Gibco) containing 2% fetal calf serum, heparin (10 IU ml1), penicillin (100 IU
ml1), and streptomycin (100 g ml1), layered onto a 34 to 51% (vol/vol)
Percoll gradient, and centrifuged at 400  g for 30 min at 4°C. The interface cells
were collected, washed twice, and suspended at a concentration of 1  106 viable
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cells ml1 in the same medium. Viability was estimated by the trypan blue
exclusion test. Cell suspensions were immediately used in phagocytosis assays.
Colonization assays. (i) Motility. Motility was measured by transferring bac-
terial colonies on MSWYE into motility medium (1% tryptone, 0.5% yeast
extract, 1% NaCl) supplemented with 0.3% (swimming) and 0.6% (swarming)
agar. Halo diameters were measured after 24 h of incubation at 28°C.
(ii) Chemotaxis. Serum and mucus from eels, as well as human serum (Sigma),
were used as substrates. Chemotaxis was evaluated using the capillary assay
TABLE 1. Bacterial strains and plasmids used in this work
Strain or plasmid Origin, genotype, and/or phenotype Reference(s) orsource
Vibrio vulnificus strains
Biotype 1
YJO16 Isolated from human blood in Taiwan, avirulent for eels, virulent for mice, genome
sequenced, opaque morphotype
15, 32
Biotype 2 serovar A
CECT5768 Isolated from diseased eel in Spain, virulent for eels, avirulent for mice,
opaque morphotype
21
CECT7030 Isolated from diseased eel in Denmark, virulent for eels, virulence for mice not
tested, opaque morphotype
21
Biotype 2 serovar E
CECT4999 Isolated from kidney of diseased eel in Spain, virulent for mice and eels,
opaque morphotype
51
CECT4864 Isolated from kidney of diseased eel in Spain, virulent for mice and eels,
opaque morphotype
51
CCUG38521 Isolated from human wound in Sweden, virulent for mice and eels,
opaque morphotype
51
CECT4866 (	 ATCC 33817) Isolated from human wound in United States, virulent for mice and eels,
opaque morphotype
3
CECT5763 Isolated from seawater in Spain, virulent for mice and eels, OM 51
4999-0 CECT4999, spontaneous Rifr, opaque morphotype This study
4999-1a CECT4999, spontaneous translucent variant This study
4999-2 CECT4999 (pCM100-gne), Rifr Cmr, opaque morphotype, gne-deficient mutant This study
4999-3 CECT4999 (pCM100-galE), Rifr Cmr, opaque morphotype, galE-deficient mutant This study
C4999-2 R99-2 with pGEMT-gne, opaque morphotype, complemented strain This study
C4999-3 R99-3 with pGEMT-galE, opaque morphotype, complemented strain This study
Biotype 2 serovar Ib
95-8-6 Isolated from diseased eel in Denmark, virulent for eels, virulence for mice not
tested, opaque morphotype
51
95-8-161 Isolated from diseased eel in Denmark, virulent for eels, virulence for mice not
tested, opaque morphotype
51
Biotype 3
11028 Isolated from human wound in Israel, avirulent for eels, virulent for mice,
opaque morphotype
11
Escherichia coli strains
XL1-Blue endA1 recA1 hsdR17 supE44 thi-1 gyrA96 relA1 lac 
F proAB lacIqZM15
Tn10 cTetr)
Stratagene
DH5 F endA hsdR17 (rK
 mK
) supE44 thi-1 rexA1 gyrA96 80lacZ 23
MC1061-pir thi thr-1 leu-6 proA2 his-4 argE2 lacY1 galK2 ara-14 xyl-5 supE44 49
S. enterica serotype Typhimurium
strains
SL3770 Expresses smooth LPS 54
SL1306 galE503, produces rough LPS of Rc chemotype 54
Plasmids
pGEM-T Easy PCR cloning vector, Ampr Promega
pCM100 pGP704 suicide plasmid, pir dependent, Cmr 61
pCM100-gne pCM100 with an internal fragment of gne, Cmr This study
pCM100-galE pCM100 with an internal fragment of galE, Cmr This study
pGEMT-gne pGEMT with the complete gne gene of CECT4999, Ampr This study
pGEMT-galE pGEMT with the complete galE gene of CECT4999, Ampr This study
a Strain obtained by passage to laboratory media as described by Biosca et al. (10).
b Strains previously identified as serotype O3 and O3/O4 (38) and reclassified as serovar I (C. Amaro, unpublished results).
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described by Larsen et al. (31). To equalize differences in random motility and
experimental variations, the chemotactic responses were expressed as the ratio of
the number of bacteria in attractant capillaries to the number of bacteria in
control capillaries filled with chemotaxis buffer.
(iii) Adherence to mucus. Ninety-six-well microtiter plates covered with eel
mucus were inoculated with 100 l of a bacterial suspension (103 to 104 CFU
ml1) in PBS-1 per well, incubated at 28°C for 24 and 72 h and 1 and 2 weeks,
washed three times with distilled water, stained with a 0.1% crystal violet solu-
tion, washed twice, and destained with 95% alcohol. The optical density at 540
nm was determined with a spectrometer (Termospectronic Helios ).
(iv) Cell surface hydrophobicity. Hydrophobicity was measured by the salt
aggregation test (SAT) using ammonium sulfate solutions (0, 0.01, 0.05, 0.1, 0.5,
1, 2, and 4 mol liter1) (33).
(v) Biofilm formation. Cells were grown in MSWYE (42). Biofilm formation
was evaluated as described by O’Toole and Kolter (44) by determining the ability
of cells to adhere to polystyrene tubes (hydrophobic surface) or glass tubes
(hydrophilic surface). The tubes were incubated at 28°C for 5 and 10 h. Biofilm
formation was quantified by addition of 200 l of 95% (vol/vol) ethanol to crystal
violet-stained samples, and the absorbance at 540 nm was determined with a
plate reader (Multiskan Askcent; Labsystems).
Eel complement fixation assay. Anti-sheep red blood cell (SRBC) (Biomedics)
serum (anti-SRBC serum) was obtained by injecting an SRBC suspension (5% in
PBS-1) plus Freund’s incomplete adjuvant (1:1) into eels using the protocol of
Esteve-Gassent et al. (18). After 2 weeks, anti-SRBC serum was collected and
inactivated by heating it at 56°C 30 min. The assay was performed on 96-well
microtiter plates as follows. One hundred microliters of inactivated anti-SRBC
serum was added to 100 l of a 5% SRBC solution in 0.01 M EDTA (tetraso-
dium salt)-gelatin-Veronal buffer (EDTA-GVB2), and the mixture was incu-
bated for 30 min at 28°C to sensitize the SRBC. Then 200-l aliquots of the
bacterial suspensions in PBS-1 were added to 200 l of nonimmune eel serum,
incubated at 28°C for 1 h, and centrifuged (400  g, 5 min, 4°C). The superna-
tants serially diluted in EDTA-GVB2 (1:100 to 1:51,200) were added either to
100 l of sensitized SRBC (1:1) to calculate 50% hemolysis due to complement
activated by the classical pathway (CH50) or to nonsensitized SRBC to calculate
50% hemolysis due to complement activated by the alternative pathway (ACH50)
after incubation at 28°C for 2 h and assessment of the relative hemoglobin
content by determination of the optical density at 540 nm with a microplate
reader (Bio-Rad). Experiments were done in triplicate. A complement fixation
index (CFI) was calculated by determining the ACH50 or CH50 ratio before and
after bacterial incubation (60).
Resistance to phagocytosis and opsonophagocytosis by eel phagocytes. To
obtain opsonized bacteria, a bacterial suspension containing 108 CFU ml1 in
PBS-1 was incubated with 10% nonimmune serum for 30 min. Then the bacte-
ricidal activity of eel phagocytes was determined as previously described (52),
with some modifications. Briefly, eel leukocytes (107 cells ml1 in Hanks bal-
anced salt solution) were dispensed into Eppendorf plates and incubated with
opsonized and nonopsonized bacteria (100 l). After 0, 1, 2, 3, and 4 h of
incubation, 50 l of saponin (0.15% in distilled water; Sigma) was added to each
well, and the microplates were incubated for 15 min at 4°C to lyse the cells.
Bacterial survival was measured both by determining bacterial culturability on
TSA-1 plates and by determining bacterial viability by reduction of 3-(4, 5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). For the latter as-
say, a solution of MTT (2 mg ml1 in distilled water) was added (50 l per well),
and plates were incubated for 15 min. MTT reduction was measured with a
multiscan spectrophotometer (Bio-Rad) at a wavelength of 630 nm. A bacteri-
cidal index was determined by dividing the absorbance/count for each sample by
the absorbance/count for the control. Experiments were performed in triplicate.
Resistance to serum and mucus. Fresh gill mucus from eels, fresh and heat-
inactivated (56°C for 60 min) human serum, and fresh and heat-inactivated
(56°C, 30 min) eel serum were used in resistance assays (2, 36). A suspension
containing 103 to 104 CFU ml1 in PBS-1 was mixed with serum mucus samples,
and the mixtures were incubated at 28°C (for eels) or 37°C (for humans) for 4 h.
Viability counting was performed on TSA-1 plates at zero time and after 4 h of
incubation.
Virulence for fish and mice. Virulence was determined by calculating the 50%
lethal dose (LD50) by the method of Reed and Muench (48), using elvers
(average weight, 10 g) and BALB/c mice (average weight, 20 g). The elvers were
kept in a 60-liter fiberglass tank containing freshwater at 26°C with a filtration
and recirculation system. Groups of six fish and six mice were inoculated intra-
peritoneally with 0.1 and 0.2 ml, respectively, of serial 10-fold dilutions of bac-
teria in PBS-1 as previously described (5, 6), and mortality was recorded daily for
a 7-day period. Mortality was considered to be caused by V. vulnificus only if the
inoculated bacterium was recovered in pure culture from internal organs (5, 6).
Statistical assays. One-way analysis of variance using the Tukey test was used
to evaluate the significance of differences in assays and was performed with the
GraphPad Prism program (version IV). Values were considered significantly
different if the P value was 0.05. Experiments were performed in triplicate.
Nucleotide sequence accession numbers. The nucleotide sequence accession
number for the VSE gne region described in this paper is EU041623, and the
nucleotide sequence accession number for the galE region is EU041622.
RESULTS
Cloning, sequence analysis, and isolation of gne and galE
mutants. Two genes (annotated VV2639 and VV3026) with
high levels of homology to the A. hydrophila epimerase genes
galE and gne (12) were found in the genome of human-patho-
genic V. vulnificus biotype 1 strain YJ016. All DNA samples
from the V. vulnificus strains shown Table 1 were positive for
the gne and galE genes in a PCR assay. The coding region of
galE of CECT4999 was 1,020 nucleotides long and showed
FIG. 1. Dendrogram showing the amino acid sequence relatedness of V. vulnificus GalE and Gne with UDP-glucose 4-epimerases of other
vibrios and related species using the TreeView software (45).
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92% homology to VV2639, while the coding region of gne was
849 nucleotides long and showed 90% homology to VV3026.
The deduced amino acid sequence revealed that galE codes for
a protein containing 339 amino acids with 89% homology to
the VV2639 protein and 65% homology to GalE of A. hy-
drophila, while gne codes for a protein containing 282 amino
acids with 71% homology to the VV3026 protein and 51%
homology to Gne of A. hydrophila (Fig. 1). galE and gne did not
show significant homology to wpbO, wpbP, or wza of V. vulni-
ficus biotype 1.
In order to isolate deficient mutants of strain CECT4999,
two plasmids that carried 584- and 531-bp DNA fragments
corresponding to incomplete copies of galE and gne, respec-
tively, were constructed. Rif- and Cm-resistant isolates were
confirmed by Southern blot hybridization with appropriate
DNA probes and were used to obtain insertion mutants.
Enzymatic activities and growth curves. Figure 2 and Ta-
ble 2 show growth curves in rich and minimal media and
epimerase activities for the wild-type strain and its deriva-
tives. The curves for the wild-type and mutant strains were
statistically similar in TSB-1 and DMM-glu and different in
DMM-gal (Fig. 2). In DMM-gal, the generation time of the
galE-deficient mutant was twice the generation time of the
wild-type strain and the gne-deficient mutant and the max-
imum population size of the galE-deficient mutant was
threefold less than the maximum population size of the
wild-type strain and the gne-deficient mutant, which suggests
that mutations in galE significantly reduce but do not elim-
inate the ability of the bacteria to grow with galactose as the
sole carbon source (Fig. 2). In fact, the wild-type strain and
the galE-deficient mutant showed both epimerase activities,
although the UDP-Gal 4-epimerase activity was lower in the
mutant (significant difference, P  0.05) (Table 2). In con-
trast, the gne-deficient mutant completely lacked UDP-
GalNAc 4-epimerase activity and had UDP-Gal 4-epimerase
activity in DMM-glu or DMM-gal that was not significantly
different from that of the wild-type strain (Table 2). E. coli
strain DH5, which lacks UDP-GalNAc 4-epimerase activ-
FIG. 2. Growth curves in TSB-1 (A) and DMM-gal (B) of strain CECT4999 and its derivatives, the gne-deficient mutant (4999-2) and the
galE-deficient mutant (4999-3), incubated at 28°C. An asterisk indicates that a value is significantly different from the value for the wild-type strain
(CECT4999) (P  0.05).
TABLE 2. UDP-Gal 4-epimerase and UDP-GalNAc 4-epimerase activities in V. vulnificus wild-type and mutant cell extracts
Strain Carbon sourcea UDP-Gal 4-epimeraseactivity (nmol min1 mg1)b
UDP-GalNAc 4-epimerase
activity (nmol min1 mg1)c
CECT4999 (wild type) Glucose 78.3  1.1 20.6  0.8
Galactose 32.6  1.0 11.9  1.2
4999-2 (gne mutant) Glucose 75.8  1.5 0.08d,e
Galactose 31.5  1.3 0.08d,e
4999-3 (galE mutant) Glucose 16.7  2.1f 20.1  0.5
Galactose 12.8  1.4f 11.1  1.6
C4999-2 (pGEMT-gne) Glucose 76.0  1.8 21.6  1.2
Galactose 30.4  1.9 10.7  2.3
C4999-3 (pGEMT-galE) Glucose 77.3  1.7 20.8  1.4
Galactose 30.9  2.2 11.7  0.8
E. coli DH5 Glucose NTg 0.08d,e
E. coli DH5 (pGEMT-gne) Glucose NT 8.4  0.9
E. coli DH5 (pGEMT-galE) Glucose NT 0.08d,e
SL3770 (wild type) Glucose 63.5  2.8 0.09d,e
SL1306 (galE mutant) Glucose 0.05d,e 0.09d,e
SL1306 (pGEMT-gne) Glucose 12.8  0.6 7.9  1.2
SL1306 (pGEMT-galE) Glucose 56.1  1.4 0.09d,e
a Each strain was grown in DMM-glu (containing 0.2% glucose) or DMM-gal (containing 0.2% galactose).
b Nanomoles of UDP-Gal converted to UDP-Glc per minute per milligram of protein.
c Nanomoles of UDP-GalNAc converted to UDP-GlcNAc per minute per milligram of protein.
d No detectable activity.
e Significantly different from the value for the wild-type strain (P  0.001).
f Significantly different from the value for the wild-type strain (P  0.05).
g NT, not tested.
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ity, had UDP-GalNAc 4-epimerase activity after comple-
mentation with gne but not after complementation with galE
(Table 2). Moreover, S. enterica serotype Typhimurium
SL1306, which is not able to grow on DMM-gal and shows no
detectable UDP-Gal 4-epimerase activity (54) (Table 2), grew
on this medium and displayed this epimerase activity after
complementation with pGEMT-gne or pGEMT-galE (Table
2). Finally, complementation of the V. vulnificus gne-deficient
mutant with pGEMT-gne and complementation of the galE-
deficient mutant with pGEMT-galE restored the wild-type
phenotype.
Surface antigens. Colonies of the wild-type strain, the gne-
deficient mutant, and the galE-deficient mutant on TSA-1 were
opaque and had similar degrees of opacity, whereas colonies of
strain 4999-1 were translucent. No apparent differences in the
OMP and ECP patterns were observed among the strains (data
not shown). In contrast, some differences in polysaccharides
were detected among the strains (Fig. 3). Thus, after immu-
nostaining of LPS-capsule extracts with anti-serovar E antibod-
ies, the wild-type strain and the galE-deficient mutant showed
the same pattern, which corresponded to the pattern for a
smooth LPS plus the capsule (Fig. 3A and B). The translucent
variant contained the whole LPS and lacked most of the cap-
sular material, especially the part corresponding to the diffuse
slowly migrating band that did not enter the separating gel
(Fig. 3A), and the gne-deficient mutant lacked most of the LPS
bands (Fig. 3B). After immunostaining of the wild-type strain
with serum absorbed with the gne-deficient mutant, only the O
antigen was observed (Fig. 3C), confirming that gne affected
LPS; and after immunostaining with serum absorbed with the
translucent variant, only the highest-molecular-weight portion
of the capsule was stained (Fig. 3D). As Fig. 3D shows, the gne-
and galE-deficient mutants were encapsulated. Electron micro-
graphs of ruthenium red-stained ultrathin sections with capsule
staining are shown in Fig. 4. Wild-type and mutant strains were
surrounded by an electron-dense layer located outside the
outer membrane (OM), which was apparently more dispersed
or absent in the translucent variant (Fig. 4). The OM of the
wild-type strain, the translucent variant, and the galE-deficient
mutant had the same appearance; however, the OM of the
gne-deficient mutant was profoundly altered, and there was a
concomitant increase in the periplasmic space, which was filled
with electron-dense material (Fig. 4). Complementation of the
gne-deficient mutant with pGEMT-gne restored the whole
structure of LPS (Fig. 3B), as well as the architecture of the
OM (Fig. 4), whereas complementation of the galE-deficient
mutant with pGEMT-galE did not alter either the OM archi-
tecture or the antigenic phenotype, which were identical to
those of the wild-type (Fig. 4 and data not shown).
Hydrophobicity and biofilm formation. There were signifi-
cant differences between strains in surface hydrophobicity,
measured by determining the lowest molarity of ammonium
FIG. 3. Immunostaining of LPS and capsule extracts with (A) rab-
bit anti-CECT4999 serum diluted 1:1,000 (lane 1, CECT4999; lane 2,
4999-1 [translucent variant]), (B) rabbit anti-CECT4999 serum diluted
1:1,000 (lane 1, 4999-3 [galE-deficient mutant]; lane 2, 4999-2 [gne-
deficient mutant]; lane 3, C4999-2 [gne-complemented strain]),
(C) rabbit anti-CECT4999 serum after absorption of the antibodies
with 4999-2 cells (anti-O-antigen serum) diluted 1:10 (lane 1,
CECT4999), and (D) rabbit anti-CECT400 serum after absorption
with 4999-1 cells (anticapsule serum) diluted 1:10 (lane 1, CECT4999;
lane 2, 4999-1; lane 3, 4999-3; lane 4, 4999-2).
FIG. 4. Electron micrographs of strains CECT4999, 4999-3 (galE-deficient mutant), 4999-2 (gne-deficient mutant), 4999-1 (translucent variant),
C4999-2 (gne-complemented strain), and C4999-3 (galE-complemented strain) after ruthenium red staining of ultrathin sections. The white arrows
indicate the electron-dense periplasmic material. Bars 	 0.1 m.
VOL. 76, 2008 ROLE OF V. VULNIFICUS SEROVAR E gne AND galE 1633
 by on M
arch 26, 2008 
iai.asm
.org
D
ow
nloaded from
 
sulfate at which the cells agglutinated (SAT assay) (P  0.05).
The SAT value for the wild-type and galE-deficient strains was
4 mol liter1, whereas the SAT value for the translucent vari-
ant and the gne-deficient mutant was 0.5 mol liter1. In accor-
dance with the SAT values, the latter strains formed more
biofilm on hydrophobic surfaces (polystyrene), whereas the
wild-type and galE-deficient strains formed more biofilm on
hydrophilic surfaces (glass) (significant differences, P  0.05)
(Fig. 5). When biofilm formation on eel skin mucus was exam-
ined, the gne-deficient mutant formed less biofilm than the
wild-type strain (significant difference, P 0.05), and the galE-
deficient mutant did not differ significantly from the wild-type
strain (Fig. 5). Complementation of the gne-deficient mutant
with pGEMT-gne completely restored the hydrophobicity and
biofilm formation patterns, whereas complementation of the
galE-deficient mutant with pGEMT-galE did not alter the sur-
face and adhesive properties (Fig. 5).
Chemotaxis and motility. Large amounts of CECT4999 and
mutant bacteria accumulated in capillaries containing eel mu-
cus compared with control capillaries containing chemotaxis
buffer. The strains also showed positive chemotaxis toward
both eel and human sera, and there were no significant differ-
ence between strains. Motility assays revealed that the swim-
ming and swarming halo diameters exhibited by the wild-type
strain, the translucent variant, and the galE-deficient mutant
were not significantly different (diameters for swimming, 10 
1 mm; diameters for swarming, 11.0  0.5 mm) and were
greater than those of the gne-deficient mutant (diameters for
swimming, 5.0  0.3 mm; diameters for swarming, 6.0  0.5
mm). Figure 6 shows the swimming behavior of the strains.
Complementation of the gne-deficient mutant with gne in-
creased the swimming and swarming halo diameters to the
wild-type strain values. Both the wild-type strain and the mu-
tants, including the gne-deficient mutant, possessed polar fla-
gella with apparently similar lengths and widths.
Resistance to eel innate immunity. (i) Resistance to mucus
and serum and sensitivity to MP and human serum trans-
ferrin. All the strains grew in gill mucus (Table 3). The wild-
type strain and the galE-deficient mutant were also resistant to
eel and human serum, whereas the translucent variant was
resistant to eel serum and sensitive to human serum and the
gne-deficient mutant was sensitive to both sera. The bacteri-
cidal effect of human serum on the translucent variant was
partially eliminated by heat inactivation; however, the bacteri-
cidal effects of human and eel sera on the gne-deficient mutant
were maintained even after heat inactivation (Table 3).
All strains were able to fix the eel complement activated by
both pathways, regardless of cell viability (Table 3). There
were no significant differences in CFI values between the wild-
type strain and the galE-deficient mutant, which fixed more
complement when it was activated by the alternative pathway
(Table 3). By contrast, the translucent variant and the gne-
deficient mutant fixed more complement than the other two
strains (significant differences, P  0.05) and showed similar
values for CFI (no significant differences) regardless of the
route of complement activation (Table 3).
The translucent variant and the gne-deficient mutant were
more sensitive to the selected MP than the wild-type strain
(significant differences, P 0.05), and the most sensitive strain
was the gne-deficient mutant (Table 3). The MICs of MP for
the galE-deficient mutant were similar to those of the wild-type
strain (Table 3). Resistance to MP, as well as to human and eel
sera, was reestablished in the gne-deficient mutant by comple-
mentation with pGEMT-gne (Table 3). Finally, the MIC of
human transferrin was the same for all strains (20 mM).
(ii) Resistance to phagocytosis and opsonophagocytosis. Eel
phagocytes were able to ingest V. vulnificus cells regardless of
whether they were opsonized by serum complement (Fig. 7),
although a significant increase in the average number of in-
gested bacteria per phagocyte (from two bacteria to five bac-
teria) was detected when bacteria were opsonized. Bacterial
survival after 1, 3, and 5 h of incubation with eel phagocytes
was analyzed. The MTT and cultivability data were similar, and
only data for cultivable bacteria recovered after phagocytosis
are shown in Fig. 7. The wild-type strain and its derivatives, the
translucent variant, and the galE-deficient mutant resisted the
killing mechanisms of eel phagocytes, and there were no sig-
nificant differences in bacterial survival (Fig. 7). In contrast,
the gne-deficient mutant was sensitive to both phagocytosis and
opsonophagocytosis. Thus, the survival percentage compared
with the wild-type strain decreased from 1 to 3 h of incubation
(significant differences, P  0.05) for phagocytosis and op-
sonophagocytosis (Fig. 7).
Virulence for mice and eels. The LD50s for mice and eels of
the wild-type strain and its derivatives are shown in Table 3.
The LD50s of the galE-deficient mutant were similar to the
LD50s of the wild-type for both eels and mice (Table 3). How-
ever, the gne-deficient mutant was avirulent for eels and
showed a significant reduction in virulence for mice, and the
FIG. 5. Biofilm formation by CECT4999 and its derivatives on
glass, polypropylene, and eel mucus measured by determining the
absorbance at 540 nm (Multiskan Askcent; Labsystems). The strains
used were strains CECT4999 (wild-type strain), 4999-1 (translucent
variant), 4999-2 (gne-deficient mutant), 4999-3 (galE-deficient mu-
tant), C4999-2 (gne-complemented strain), and C4999-3 (galE-comple-
mented strain). An asterisk indicates that the value is significantly
different from the value for the wild-type strain (P  0.001).
FIG. 6. Swimming behavior of strains CECT4999 (wild-type
strain), 4999-2 (gne-deficient mutant), and 4999-3 (galE-deficient mu-
tant).
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translucent variant also showed a significant reduction in vir-
ulence for both hosts (Table 3). Complementation with
pGEMT-gne completely restored the virulence for fish or mice
(the LD50s were similar to those of the wild-type strain) in
the gne-deficient mutant, while no changes were observed in
the galE-deficient mutant after complementation with and
pGEMT-galE (Table 3).
DISCUSSION
This work aimed to establish the role of gne and galE in the
biosynthesis of surface polysaccharides, as well as in virulence
for eels and humans of the zoonotic serovar of V. vulnificus
biotype 2. Putative homologues of these genes were first iden-
tified in the genome of the human-pathogenic V. vulnificus
biotype 1 isolate YJ016 and were amplified and sequenced in
the VSE isolate CECT4999. The sequences of VSE strain
genes (galE and gne) were highly similar (90 to 92%) to the
sequences of their homologs in biotype 1 strain YJ016. In
addition, both genes were found by PCR in all V. vulnificus
isolates tested regardless of biotype and serovar.
The enzymatic analyses performed with the mutants and the
complemented strains, including the analyses performed with
the complemented E. coli and S. enterica serovar Typhimurium
strains, confirmed that gne encodes an epimerase with UDP-
GalNAc 4-epimerase activity that is responsible for the con-
version of UDP-GalNAc to UDP-GlcNAc and that galE en-
codes a protein with UDP-Gal 4-epimerase activity that is
responsible for the conversion of UDP-Gal to UDP-Glc. In
addition, the experiments performed with Salmonella suggest
that gne encodes an epimerase with both UDP-GalNAc and
UDP-Gal activities. In accordance with this observation, the V.
vulnificus gne mutant exhibited only a very small reduction in
the UDP-Gal 4-epimerase activity, probably because the main
enzyme activity is due to GalE. At the same time, the reduced
UDP-Gal 4-epimerase activity observed for the V. vulnificus
galE mutant is supported by the fact that Gne can have re-
duced UDP-Gal 4-epimerase activity compared to GalE (Ta-
ble 2). A similar situation has been described in A. hydrophila
(12) and Campylobacter jejuni (8), in which Gne exhibits dou-
ble activity as a UDP-GalNAc 4-epimerase and a UDP-Gal
4-epimerase and could supply the function of GalE. These
results contrast with the results obtained for E. coli and S.
enterica serovar Typhimurium, in which the GalE protein is the
only UDP-Gal 4-epimerase (54). In these enterobacteria, mu-
tations in galE are correlated with changes in the LPS chemical
structure produced by an O-antigen-deficient LPS (54). In
addition, gne and galE, as well as the putative proteins that they
encode, were highly homologous to Aeromonas gne and galE
genes and proteins, respectively, suggesting that the two genes
could correspond to gne and galE and could encode UDP-
GalNAc 4-epimerase and UDP-Gal 4-epimerase activity, re-
spectively. V. vulnificus VSE gne and galE do not show signif-
icant homology with the recently described gene wbpP, which
codes for a UDP-GlcNAc epimerase essential for capsule bio-
synthesis in biotype 1 strains (47).
The gne-deficient mutant had profound alterations in the
cellular envelope that were visible by electron microscopy.
Thus, the OM displayed irregular morphology, limiting the
enlarged periplasmic space, in which electron-dense material
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accumulated. The alterations in the OM did not affect the
ability of the mutant to grow in complex media, since the
growth curves were not statistically different from those of
the wild-type strain. The gne-deficient mutant lacked O antigen
but contained the capsular polysaccharide. In fact, cells visu-
alized in the micrographs were surrounded by ruthenium red-
stained material and developed colonies with an opaque mor-
photype on agar plates. The gne-deficient mutant produces
deficient-LPS, probably because the O-polysaccharide chain
contains GlcNAc residues in each of its repeated units, like A.
hydrophila serotype 034 (12) or Yersinia enterocolitica serotype
0:8 (7). This sugar was previously found in the capsule of the
type strain of the species, which is a biotype 1 strain(22). The
capsule of VSE strains does not seem to contain this sugar
since the gne-deficient strain is a capsulated strain. In fact, at
least 13 different K antigens have been described in the species
(24).
Mutation in the gne gene of V. vulnificus VSE strains deeply
affected the virulence phenotype of this zoonotic serovar. Eel
vibriosis is a septicemic process comprising two steps: gill col-
onization and blood invasion with subsequent colonization of
the internal organs (37, 56). The wild-type strain resisted the
bactericidal action of gill mucus, was strongly attracted by it,
and formed biofilms on mucus-coated plates, which correlates
with its natural route of infection. In contrast, the gne-deficient
mutant, although resistant to and chemoattracted by gill mu-
cus, showed a significantly reduced ability to form biofilms on
mucus compared with the wild-type strain. The translucent
variant, which lacks most of the capsular material and retains
the O antigen, formed as much biofilm on gill mucus as the
wild-type strain. This result suggests that the O antigen rather
than the capsule is involved in gill colonization, probably by
facilitating attachment and biofilm formation on gills. Similar
functions have been reported for the O antigen in Vibrio chol-
erae, since O-antigen-deficient V. cholerae strains are also de-
ficient in mucus colonization (39).
The reduced motility observed in the gne-deficient mutant
on semisolid surfaces seems not to be due to the loss of the
flagellum or to defective flagellar biogenesis, since cells were
motile in liquid medium and had a flagellum that was appar-
ently the same length as the flagellum of the wild-type strain.
Instead, the reduced swarming and swimming could be ex-
plained by the loss of a negatively charged O antigen, which
would reduce the surface “wetability” required for colony ex-
pansion, as described previously for O-antigen-deficient mu-
tants of S. enterica serovar Typhimurium (54).
It has been hypothesized that resistance to the innate de-
fenses of the eel is the key step for colonization of the internal
medium and death by septicemia (56). V. vulnificus VSE strains
can survive in eel serum and resist the killing mechanisms of
eel phagocytes in vitro, and spontaneous alterations in capsule
and LPS that affect serum resistance have been described (2,
5). The gne-deficient mutant was sensitive to fresh eel serum
and phagocytosis/opsonophagocytosis. The translucent sponta-
neous variant, which retains the O antigen and lacks most of
the capsule, resisted the bactericidal action of eel serum; how-
FIG. 7. Bactericidal activity of phagocytes from spleen, blood, and head kidney against nonopsonized or opsonized VSE strains. The strains
used were strains CECT4999 (wild-type strain), 4999-1 (translucent variant), 4999-2 (gne-deficient mutant), 4999-3 (galE-deficient mutant),
C4999-2 (gne-complemented strain), and C4999-3 (galE-complemented strain). An asterisk indicates that the value is significantly different from
the value for the wild-type strain (P  0.001).
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ever, it grew significantly less than the wild-type strain and also
resisted phagocytosis/opsonophagocytosis. Both strains fixed
significantly more eel complement than the wild-type strain,
especially when complement was activated by the classical
pathway. These results suggest that the capsule and the O
antigen may interfere with the deposition of natural antibodies
and/or lectins on their natural targets (LPS core and other
targets). The gne-deficient mutant was still sensitive to serum
after inactivation by heating, which suggests that the loss of the
O antigen makes the bacterium sensitive to a thermoresistant
component naturally present in fresh serum or secreted by eel
phagocytes. This extreme sensitivity to both eel serum and
killing by phagocytes was correlated with a high level of sen-
sitivity to cationic peptides present in eel serum and secreted
by eel phagocytes (40), especially sensitivity to polymyxin B,
which was significantly higher than the sensitivity of the trans-
lucent variant. The gne-deficient mutant was avirulent for eels,
while the translucent variant was virulent for eels but exhibited
a significantly higher LD50 than the wild-type strain. Thus, the
resistance to the innate defenses of eels was well correlated to
the degree of virulence for eels.
To evaluate the role of gne gene in human virulence, addi-
tional experiments to examine survival in human serum and
virulence for mice were performed. Previous studies suggested
that capsule was essential for human serum resistance by VSE
cells and for virulence for mice (5). The results obtained in the
present work confirm the previous findings since the translu-
cent variant was sensitive to human serum and showed atten-
uated virulence for mice. As expected, the gne-deficient mutant
was sensitive to human complement, even after heating, and
showed attenuated virulence for mice, which confirms the role
of the O antigen in resistance to both human and fish sera, as
well as in virulence for both hosts. All these virulence traits
were rescued by complementation of a mutant with the single
gene gne.
Currently, eel vibriosis is kept under control on fish farms by
vaccination by immersion with Vulnivaccine, a conventional
bacterin that provides protection against vibriosis for 6 to 12
months (20). However, this vaccine and vaccination procedure
do not eliminate the pathogen, which can survive on the eel
surface inside biofilms (56), making the healthy carrier eels a
risk to human health. The gne-deficient mutant is avirulent for
fish and probably avirulent for humans since it was sensitive to
human serum and showed attenuated virulence for mice, and
at the same time, it can grow efficiently in complex media. This
mutant could be a good candidate for development of a new
live vaccine against eel vibriosis, at least against the disease
caused by V. vulnificus VSE strains.
In conclusion, gne plays an essential role both in O-antigen
biosynthesis of the LPS and in virulence for humans and eels of
VSE cells, whereas galE does not play a role in either OM
biosynthesis or virulence. Further studies are under way to
develop and validate a new live vaccine against fish vibriosis
using the gne-deficient mutant, which could also prevent zoo-
nosis caused by V. vulnificus VSE strains.
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